A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST).

See ANZCTR for full trial details >

 

Trial Summary:

To determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.

Supported By:

NHMRC CTC; EORTC; SSG

Eligibility:

Adults with histologically confirmed, measurable metastatic GIST, who have received no prior treatment for metastatic disease. Patients who are currently taking, and have had up to 21 days of uninterrupted treatment with 400mg daily of imatinib are eligible to participate in this study.

Registration ID:

ACTRN12614000950662 & NCT02365441

Participation:

International

Australian Lead Group:

AGITG

Status:

Open

Activation Date:

16/02/2015

Chairs:

Desmond Yip (ANZ Study Chair), Heikke Joensuu (International Study Chair)

Contact:

altgist.study@sydney.edu.au